Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31645967 | 1.00 | KDM4E (0.61) | KDM4EALOX15TSHRACMSDTDP1 | |
| Hydrochloric Acid SCHEMBL1242328 | 0.98 | KDM4E (0.59) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL24453826 | 0.88 | KDM4E (0.48) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL26547504 | 0.85 | KDM4E (0.57) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL30487682 | 0.84 | PIM1 (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2891884 | 0.84 | PIM1 (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2352264 | 0.83 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL31591148 | 0.83 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| Hydrochloric Acid SCHEMBL3984366 | 0.82 | PIM1 (0.43) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL20202796 | 0.82 | NPSR1 (0.43) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048156-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2026-02-19 | — | — | US | claimed |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2025-07-24 | — | — | US | claimed |
| WO-2025125621-A1 | CANCER-ASSOCIATED PROTEIN-TARGETED STRONG OR COVALENTLY BINDING PRECURSOR COMPOUNDS AND RADIOTRACERS | RADIOVAXX GMBH (DE) | 2025-06-19 | — | — | WO | claimed |
| EP-4351663-A1 | TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2024-04-17 | — | — | EP | claimed |
| EP-4281119-A1 | PRECURSOR MARKER AND RADIOTRACER FOR NUCLEAR-MEDICAL DIAGNOSIS AND THERAPY OF BONE-METASTATIC PROSTATE CANCER | SCV - SpezialChemikalienVertrieb GmbH (DE) | 2023-11-29 | — | — | EP | claimed |
| WO-2022258637-A1 | TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Atoms for Cure GmbH (DE) | 2022-12-15 | — | — | WO | claimed |
| EP-4076534-A1 | SMART DRUG DELIVERY SYSTEM AND PHARMACEUTICAL KIT FOR DUAL NUCLEAR MEDICAL CYTOTOXIC THERANOSTICS | SCV - SpezialChemikalienVertrieb GmbH (DE) | 2022-10-26 | — | — | EP | claimed |
| WO-2022157277-A1 | PRECURSOR MARKER AND RADIOTRACER FOR NUCLEAR-MEDICAL DIAGNOSIS AND THERAPY OF BONE-METASTATIC PROSTATE CANCER | SCV - SpezialChemikalienVertrieb GmbH (DE) | 2022-07-28 | — | — | WO | claimed |
| US-20260048156-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2026-02-19 | — | — | US | disclosed |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2025-07-24 | — | — | US | disclosed |
| WO-2025125335-A1 | CYTOTOXIC OR RADIOPHARMACEUTICAL COMPOUND WITH SULFUR FLUORIDE EXCHANGE GROUP | RADIOVAXX GMBH (DE) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025125621-A1 | CANCER-ASSOCIATED PROTEIN-TARGETED STRONG OR COVALENTLY BINDING PRECURSOR COMPOUNDS AND RADIOTRACERS | RADIOVAXX GMBH (DE) | 2025-06-19 | — | — | WO | disclosed |
| EP-4452326-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-4351663-A1 | TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2024-04-17 | — | — | EP | disclosed |
| US-5773411-A | CARDIOVASCULAR DISORDERS AND BRAIN DISORDERS AND COAGULANTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0794789-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5602098-A | ANTICANCER AGENT | UNIVERSITY OF PITTSBURGH (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996021456-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1996-07-18 | — | — | WO | disclosed |
| EP-0672059-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994011398-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048156-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | FAP, ALK, FIBP | KDM4E 2871/4885ALOX15 4764/4885TSHR 804/4885 |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | TK1, TK2, TMT1A | KDM4E 4412/4885ALOX15 3849/4885TSHR 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.